Mobilization of hematopoietic progenitor stem cells in allogeneic setting with lenograstim by subcutaneous injection, in daily or twice‐daily dosing: a single‐center prospective study with historical control. Issue 8 (9th April 2015)

• Record Type: Journal Article
• Authors: Martino, Massimo; Moscato, Tiziana; Barillà, Santina; Dattola, Antonia; Pontari, Antonella; Fedele, Roberta; Furlò, Giuseppe; Marzia Stilo, Carmen; Alberto Gallo, Giuseppe; Tripepi, Giovanni
• Is Part Of: Transfusion. Volume 55:Issue 8(2015)
• Page Start: 2032
• Page End: 2038
• Publication Date: 2015-04-09
• Subjects: Hematology -- Periodicals; Blood -- Transfusion -- Periodicals; Blood Group Antigens -- Periodicals; Blood Preservation -- Periodicals; Blood Transfusion -- Periodicals; 615
• DOI: 10.1111/trf.13117
• Languages: English
• ISSNs: 0041-1132

Abstract

<abstract abstract-type="main"> <title> <x xml:space="preserve">Abstract</x> </title> <sec id="trf13117-sec-0001" sec-type="section"> <title>BACKGROUND</title> <p>Although the mobilization of hematopoietic progenitor stem cells from healthy donors (HDs) using granulocyte–colony‐stimulating factor is widely used, the ideal method for the administration of the cytokine has not yet been determined.</p> </sec> <sec id="trf13117-sec-0002" sec-type="section"> <title>STUDY DESIGN AND METHODS</title> <p>Seventy‐five consecutive HDs received lenograstim (LENO) as mobilization agent. LENO was given subcutaneously at a dose of 10 µg/kg in a once‐daily dose (ODD) every 24 hours. Results were compared with a historical control group of 181 HDs treated with 5 µg/kg LENO twice‐daily dose (TDD) with a time interval of 12 hours.</p> </sec> <sec id="trf13117-sec-0003" sec-type="section"> <title>RESULTS</title> <p>CD34+ cell concentrations evaluated on Day 4 and on Day 5 were 45 × 10<sup>6</sup> (range, 6 × 10<sup>6</sup>‐217 × 10<sup>6</sup>)/L and 75 × 10<sup>6</sup> (range, 7 × 10<sup>6</sup>‐279 × 10<sup>6</sup>)/L with ODD versus 36 × 10<sup>6</sup> (range, 3 × 10<sup>6</sup>‐200 × 10<sup>6</sup>)/L and 55 × 10<sup>6</sup> (range, 3 × 10<sup>6</sup>‐738 × 10<sup>6</sup>)/L with TDD (p = 0.067 and p = 0.001). The collected CD34+ cell counts in first apheresis procedure were 5.6 × 10<sup>6</sup> ± 2.9 × 10<sup>6</sup> and 5.7 × 10<sup>6</sup> ± 3 × 10<sup>6</sup>/kg donor and recipient body weight in the ODD versus 5.4 × 10<sup>6</sup> ± 3.8 × 10<sup>6</sup> and 5.3 × 10<sup>6</sup> ± 3.5 × 10<sup>6</sup>/kg in the TDD cohort, respectively (p = 0.08 and p = 0.02). Five HDs (6.7%) mobilized CD34+ cells of fewer than 2 × 10<sup>6</sup>/kg recipient body weight in the ODD group compared with seven HDs (3.9%) in the TDD group (p = 0.3).</p> </sec> <sec id="trf13117-sec-0004" sec-type="section"> <title>CONCLUSIONS</title> <p>Once‐daily administration of LENO is at least as effective as twice‐daily administration for the mobilization of CD34+ cells in HDs.</p> </sec> </abstract>